The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.
 
Sarmad Sadeghi
Consulting or Advisory Role - Cardiff Oncology (I); Cardinal Health
Research Funding - Merck; Pfizer
 
Melissa Plets
No Relationships to Disclose
 
Primo N Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Janssen; Janssen; Janssen; Janssen
Research Funding - Janssen Biotech (Inst); Janssen Biotech (Inst); Janssen Biotech (Inst); Janssen Biotech (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Catherine Tangen
No Relationships to Disclose
 
Rick Bangs
Consulting or Advisory Role - Nonagen Bioscience; Nonagen Bioscience; Nonagen Bioscience; Nonagen Bioscience
Other Relationship - ASCO; ASCO; ASCO; ASCO; Bladder Cancer Advocacy Network; Bladder Cancer Advocacy Network; Bladder Cancer Advocacy Network; Bladder Cancer Advocacy Network; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Institute for Clinical and Economic Review; Institute for Clinical and Economic Review; Institute for Clinical and Economic Review; Institute for Clinical and Economic Review; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Cancer Institute; National Comprehensive Cancer Network; National Comprehensive Cancer Network; National Comprehensive Cancer Network; National Comprehensive Cancer Network; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; SWOG; University of Puerto Rico; University of Puerto Rico; University of Puerto Rico; University of Puerto Rico
 
Seth P. Lerner
Stock and Other Ownership Interests - C2i genomics; C2i genomics; C2i genomics; C2i genomics
Honoraria - Annenberg Center for Health Sciences at Eisenhower (ACHS); Annenberg Center for Health Sciences at Eisenhower (ACHS); Annenberg Center for Health Sciences at Eisenhower (ACHS); Annenberg Center for Health Sciences at Eisenhower (ACHS); Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Grand Rounds in Urology; Grand Rounds in Urology; Grand Rounds in Urology; Grand Rounds in Urology; UroToday; UroToday; UroToday; UroToday
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Aura Biosciences; Aura Biosciences; Aura Biosciences; Aura Biosciences; Bristol-Myers Squibb Foundation/Janssen; Bristol-Myers Squibb Foundation/Janssen; Bristol-Myers Squibb Foundation/Janssen; Bristol-Myers Squibb Foundation/Janssen; C2i Genomics; C2i Genomics; C2i Genomics; C2i Genomics; Ferring; Ferring; Ferring; Ferring; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Pfizer/EMD Serono; Protara Therapeutics; Protara Therapeutics; Protara Therapeutics; Protara Therapeutics; Stimit; Stimit; Stimit; Stimit; Vaxiion; Vaxiion; Vaxiion; Vaxiion; Verity Pharmaceuticals; Verity Pharmaceuticals; Verity Pharmaceuticals; Verity Pharmaceuticals
Research Funding - Endo Pharmaceuticals; Endo Pharmaceuticals; Endo Pharmaceuticals; Endo Pharmaceuticals; FKD Therapies; FKD Therapies; FKD Therapies; FKD Therapies; Japan BCG Laboratory; Japan BCG Laboratory; Japan BCG Laboratory; Japan BCG Laboratory; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma; Vaxiion; Vaxiion; Vaxiion; Vaxiion; Viventia Biotech; Viventia Biotech; Viventia Biotech; Viventia Biotech
Patents, Royalties, Other Intellectual Property - TCGA expression subtype singel patient classifier; TCGA expression subtype singel patient classifier; TCGA expression subtype singel patient classifier; TCGA expression subtype singel patient classifier
Other Relationship - Bladder Cancer Journal; Bladder Cancer Journal; Bladder Cancer Journal; Bladder Cancer Journal; UpToDate; UpToDate; UpToDate; UpToDate
 
Thomas W. Flaig
Leadership - Aurora Oncology; Aurora Oncology; Aurora Oncology; Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology; Aurora Oncology; Aurora Oncology; Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Seagen; Seagen; Seagen; Seagen
Research Funding - Agensys; Agensys; Agensys; Agensys; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Aragon Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; astrazeneca/MedImmune; astrazeneca/MedImmune; astrazeneca/MedImmune; astrazeneca/MedImmune; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bavarian Nordic; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Dendreon; Dendreon; Dendreon; Dendreon; Exelixis; Exelixis; Exelixis; Exelixis; GTx; GTx; GTx; GTx; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; La Roche-Posay; La Roche-Posay; La Roche-Posay; La Roche-Posay; Lilly; Lilly; Lilly; Lilly; Medivation; Medivation; Medivation; Medivation; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sanofi; Sanofi; Sanofi; Sanofi; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Seagen; Sotio; Sotio; Sotio; Sotio; Tokai Pharmaceuticals; Tokai Pharmaceuticals; Tokai Pharmaceuticals; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.; The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Daniel P. Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Amgen; Amgen; Amgen; Amgen; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Exelixis; Exelixis; Exelixis; Exelixis; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Monopteros Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics; Regeneron; Regeneron; Regeneron; Regeneron; Roche; Roche; Roche; Roche; Seagen; Seagen; Seagen; Seagen; Urogen pharma; Urogen pharma; Urogen pharma; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Agensys (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Endocyte (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Innocrin Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Medivation (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Progenics (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Replimune (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Expert Testimony - Celgene; Celgene; Celgene; Celgene; sanofi; sanofi; sanofi; sanofi
 
Ian M Thompson
Consulting or Advisory Role - Magforce; Magforce; Magforce; Magforce; Profound Medical; Profound Medical; Profound Medical; Profound Medical
Research Funding - MagForce; MagForce; MagForce; MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme